The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Pancancer survival analysis of cancer hallmark genes
Open accessAbstract
Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E−16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E−10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E−12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E−10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E−05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E−07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E−07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E−05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G. M., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M. A. M., Gelder, M. E. M., Yu, J. X., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,831
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Cited by
Sorted by citations
Items 801–900 of 1,000
Differential expression of NSL1 in cancer of the head and neck: oral squamous cell carcinoma.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/v2c4d · Cited by 1
Differential expression of C1QTNF6 in cancer of the head and neck: oral squamous cell carcinoma.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/sf95w · Cited by 1
LOCC: a novel visualization and scoring of cutoffs for continuous variablesPreprint
Luo, G., & Letterio, J. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.11.536461 · Cited by 1
Differential expression of PTGER3 in cancer of the cervix.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/7b3m8 · Cited by 1
Lin, Z., Du, Y., Duan, Y., Zhang, W., Huang, Z., Yin, X., Ma, T., Xie, Y., & Che, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2971625/v1 · Cited by 1
Dysregulation of cell state dynamics during early stages of serous endometrial carcinogenesisPreprint
Flesken‐Nikitin, A., Pirtz, M. G., Ashe, C. S., Ellenson, L. H., Cosgrove, B. D., & Nikitin, A. Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.15.585274 · Cited by 1
Perturbation of BRMS1 interactome reveals pathways that impact cell migrationPreprint
Zimmermann, R. C., Sardiu, M. E., Manton, C. A., Miah, S., Banks, C. A. S., Adams, M. K., Koestler, D. C., Hurst, D. R., Edmonds, M. D., Washburn, M. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.04.429764
Sun, K., Chen, R., Li, J., & Luo, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-453638/v1
Chen, J., Zou, J., Zeng, J., Zeng, T., Hu, Q.-H., Bai, J.-H., Tang, M., & Li, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-487176/v1
Lu, P., Jiang, J., & Lu, J. (2021) · Research Square · doi:10.21203/rs.3.rs-435154/v1
Prognostic Significance of Cofilin Isoforms in Patients With Pancreatic Ductal Adenocarcinoma
Islam, S., Kitagawa, T., & Kuramitsu, Y. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609821
Gao, Y., Chen, Y., Li, F., Wu, R., Zeng, D., Tan, F., Liu, X., Li, X., Li, Y., Su, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-517084/v1
MEX3A and MEX3B as Potential Prognostic Indicators in Stomach AdenocarcinomaPreprint
Zou, J., Huang, Y., Wu, Z., Xie, H., Wang, R., & Xing, C. (2021) · Research Square · doi:10.21203/rs.3.rs-599484/v1
Over-expression of inositol 1,4,5-trisphosphate receptor type 3 in human endometrial cancer.Preprint
Mamoor, S. (2021) · Research Square · doi:10.21203/rs.3.rs-582011/v1
PTEN mutant NSCLC require ATM to suppress pro-apoptotic signalling and evade radiotherapyPreprint
Fischer, T., Hartmann, O., Reissland, M., Prieto‐Garcia, C., Klann, K., Schülein‐Völk, C., Polat, B., Hartmann, E., Rosenfeldt, M. T., Münch, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.24.453632
Identification of Novel Long non-coding RNAs and Expression Analyses in Rectal Neuroendocrine TumorsPreprint
Padwal, M. K., & Basu, B. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.18.452620
Cao, B., Deng, H., Cui, H., Zhao, R., Li, H., Wei, B., & Chen, L. (2021) · Research Square · doi:10.21203/rs.3.rs-650761/v1
Duan, L., lin, J. X., Lin, T., xiao, Y. Y., Juan, W., qian, L. Q., & lan, Z. X. (2021) · Research Square · doi:10.21203/rs.3.rs-757552/v1
Chen, X., Yu, D., Zhou, H., Zhang, X., Hu, Y., Zhang, R., Gao, X., Lin, M., Guo, T., & Zhang, K. (2021) · Research Square · doi:10.21203/rs.3.rs-757231/v1
Fischer, T., Hartmann, O., Reissland, M., Prieto‐Garcia, C., Klann, K., Schülein‐Völk, C., Baluapuri, A., Polat, B., Hartmann, E., Rosenfeldt, M. T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-847293/v1
Wu, X., Liu, F., Liu, S., Song, C., & Wu, H. (2021) · Research Square · doi:10.21203/rs.3.rs-851414/v1
Hypoxia Induced HMMR Promotes the NSCLC ProgressionPreprint
Duan, L., lin, J. X., Tan, L., xiao, Y. Y., Wang, J., qian, L. Q., & lan, Z. X. (2021) · Research Square · doi:10.21203/rs.3.rs-864699/v1
Zheng, A., Bai, J., Ha, Y., Wang, B., Zou, Y., Wu, C., Xing, J., Zheng, S., Shen, Z., Luo, B., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-847345/v1
Hu, Y., & Shen, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-892580/v1
Wagle, M. M., Rao, A. K., Kabekkodu, S. P., & Mallya, S. P. (2021) · Research Square · doi:10.21203/rs.3.rs-879048/v1
Zhao, C., Liu, L., He, Q., Li, Y., Jiang, J., Chen, Y., Li, X., Tang, Y., Li, Y., Zhou, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-919310/v1
Chen, W., Li, B., Ni, C., Jia, F., Li, J., Huang, H., & Xia, W. (2021) · Research Square · doi:10.21203/rs.3.rs-899442/v1
谢, 国. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1110699
van den Driest, L., Johnson, C. H., Rattray, N. J. W., & Rattray, Z. (2021) · medRxiv · doi:10.1101/2021.11.10.21266196
Altered expression of Api5 affects breast carcinogenesis by modulating FGF2 signallingPreprint
Abhijith, K., Panda, D., Malaviya, R., Gaidhani, G., & Lahiri, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.02.466904
MAL suppresses OSCC tumorigenesis by maintaining epithelial cell differentiationPreprint
Zhu, X., Liu, Z., Qi, S., Zou, X., Lu, T., Xing, K., Qin, X., Wang, X., Yan, M., Xu, Q., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.01.470749
TMPRSS7 expression associates with survival in triple negative breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/k65rw
CCDC102A is a differentially expressed gene in brain metastatic human breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/nqe6v
Over-expression of Cyclin D1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/jms5e
Identification of Prognostic Biomarkers Among DAAM1, FHOD1,FMN2 and INF2 in Breast Cancer PatientsPreprint
Dai, Y., Li, F., Kong, W.-J., Zhang, X., Wang, M., Ma, H., & Wang, Q. (2021) · Research Square · doi:10.21203/rs.3.rs-742870/v1
Over-expression of KPNA2 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/aktjc
Zhao, F., Chang, J., Wang, W., Sun, X., Ma, X., Zhao, P., Wang, Y., & Yang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-947966/v1
Maojing, W., Li, W., Ding, L., & Han, Z. (2021) · International Journal of Pharmaceutical Sciences and Developmental Research · doi:10.17352/ijpsdr.000035
Over-expression of cyclin B1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/hvsxe
Over-expression of TLR3 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/v89fh
Over-expression of cyclin B2 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/je3v2
Over-expression of CDC20 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/xybzw
Over-expression of cathepsin Z in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/4nrz6
Lao, S., Chen, Z., Xiong, Y., He, M., Zheng, Y., Liu, X., Zhang, J., He, J., & Liang, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1363802/v1
Li, R., Tang, K. L., & Li, Q. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10104
Chen, L., Zou, W., Xu, J., Zhang, L., Jiang, X., & Ni, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1571512/v1
Wagle, M. M., Rao, A. K., Kabekkodu, S. P., & Mallya, S. P. (2022) · Research Square · doi:10.21203/rs.3.rs-879048/v2
Lao, S., Chen, Z., Zhang, Y., Li, J., Liang, H., Zheng, Y., Liu, X., Wang, W., & Liang, W. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-1-1476
Over-expression of mucin 1, cell surface associated in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/3rwxy
Over-expression of KIAA0101 (PCLAF) in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/mknyu
Over-expression of protein regulator of cytokinesis 1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/7xw3u
LYZL2 expression associates with survival in triple negative breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/txdps
Over-expression of adenosine kinase in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/hc3er
Over-expression of voltage dependent anion channel 1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/h7erq
Over-expression of ubiquitin conjugating enzyme E2 C in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/7v9qx
Over-expression of ALG8, alpha-1,3-glucosyltransferase in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/2b6h5
ISYNA1 expression associates with survival in triple negative breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/k4g26
Over-expression of DLG associated protein 5 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/wu3mk
Over-expression of ubiquitin conjugating enzyme E2 L3 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/dvhn7
Over-expression of pituitary tumor-transforming 1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/tdvsa
Over-expression of ADP ribosylation factor like GTPase 4C in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/7rzf8
KRTAP21-1 expression associates with survival in triple negative breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/xkwgp
Over-expression of bora, aurora kinase A activator in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/xyed8
Deng, Y., Chen, J., Luo, X., Zeng, T., Ye, D., Li, Y., Tang, M., & Zhang, Y.-P. (2021) · Research Square · doi:10.21203/rs.3.rs-487176/v2
Over-expression of topoisomerase (DNA) II alpha in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/k4qpv
Differential expression of a pseudogene of TPTE2 in cancers of the breast.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/cs6pz
TMEM71 expression associates with survival in triple negative breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/djgqs
Over-expression of proteasome 26S subunit, non-ATPase 14 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/67c5b
Over-expression of PDZ binding kinase in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/s924m
Over-expression of ISG15 ubiquitin-like modifier in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/by9wh
Over-expression of centrosomal protein 55 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/4esjx
Over-expression of keratin 18 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/kvcw3
Over-expression of insulin degrading enzyme in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/pfec3
Over-expression of tumor protein D52-like 1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/ba9jy
Over-expression of hyaluronan mediated motility receptor in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/qas7f
Over-expression of annexin A1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/jfpgn
Over-expression of cyclin dependent kinase inhibitor 3 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/pbcd4
Over-expression of Rac GTPase activating protein 1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/27xgs
TTC5 expression associates with survival in triple negative breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/yjv38
Over-expression of MLX, MAX dimerization protein in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/4yhjs
Over-expression of keratin 8 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/prxqv
Over-expression of cytoskeleton associated protein 2 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/gb6dq
Over-expression of tubulin beta 4B class IVb in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/wqbpg
Over-expression of glutamic-oxaloacetic transaminase 1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/sej8u
Over-expression of thymidylate synthetase in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/f6qry
Over-expression of tubulin gamma 1 in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/g96u2
DNAJC28 expression associates with survival in triple negative breast cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/v45h2
Over-expression of adenine phosphoribosyltransferase in human endometrial cancer.Preprint
Mamoor, S. (2021) · doi:10.31219/osf.io/qwmu3
Metadata
- Authors
- Nagy, Á., Munkácsy, G., & Győrffy, B.
- Affiliations
- Semmelweis University (HU)
- Corresponding author
- Győrffy, Balázs
- Venue
- Scientific Reports
- Published
- 2021-03-15
- Volume
- 11
- Issue
- 1
- Pages
- 6047-6047
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7961001
- OpenAlex
- W3139511935
- Cited by
- 1,381
- References
- 40
- Citations by year
- 2026: 38 · 2025: 84 · 2024: 145 · 2023: 504 · 2022: 311 · 2021: 298
- FWCI
- 101.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Semmelweis Egyetem
- Innovációs és Technológiai Minisztérium (ÚNKP-19-3, 2018-2.1.17-TET-KR-00001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- prognostic gene signature, survival analysis, genomic instability, invasion and metastasis, replicative immortality, cell death resistance, angiogenesis, tumor suppressor, BRCA1, RUNX1, SERPINE1, CDK1, E2F1, epiregulin, c-Myc, clear cell renal cell carcinoma, low-grade glioma, cervical cancer, bladder cancer, thyroid cancer, glioblastoma, tissue specificity, targeted therapy
- MeSH terms
- RNA-Seq, Humans, Neoplasms, Biomarkers, Tumor, Survival Rate, Disease-Free Survival, Databases, Nucleic Acid, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
